SUPPORT for Patients and Communities Reauthorization Act of 2025

The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483) was signed into law on December 1, 2025, becoming Public Law 119-44. This Act reauthorizes and revises Department of Health and Human Services (HHS) programs addressing substance use disorders, overdoses, and mental health for fiscal years 2026 through 2030. The bill's passage ensures continued federal support for a wide range of programs, including those for pregnant and postpartum women, youth prevention and recovery, housing for individuals in recovery, and loan repayment for healthcare providers treating substance use disorders. This legislation authorizes the continuation of federal programs, establishing spending ceilings rather than appropriating specific funds. Actual funding levels will depend on subsequent appropriations bills passed by Congress annually. However, the reauthorization itself signals a commitment to these programs, creating a predictable demand environment for related healthcare services and products. The mechanism involves grants and other programs administered by HHS, which will flow to states, local entities, and healthcare providers. Structural winners from this reauthorization include diagnostic companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX), which provide testing services relevant to substance use disorders and mental health. Healthcare providers such as HCA Healthcare, Inc. ($HCA) and Universal Health Services, Inc. ($UHS), which operate hospitals and behavioral health facilities, are also positioned to benefit from increased program funding and patient demand. Pharmaceutical distributors like McKesson Corporation ($MCK) and Cardinal Health, Inc. ($CAH) will see sustained demand for related medications and supplies. AMN Healthcare Services, Inc. ($AMN), a healthcare staffing company, may also experience increased demand for specialized personnel. Recent market data for these companies shows varied performance. Labcorp Holdings Inc. ($LH) is currently at $274.46, up 4.12% over the last 7 days. Quest Diagnostics Incorporated ($DGX) is at $198.96, with a 0.91% increase over 7 days. HCA Healthcare, Inc. ($HCA) is at $483.92, showing a 3.44% increase in the last 7 days. In contrast, AMN Healthcare Services, Inc. ($AMN) is at $18.56, down 0.91% over 7 days and 17.66% over 30 days. McKesson Corporation ($MCK) is at $856.77, down 0.4% over 7 days, and Cardinal Health, Inc. ($CAH) is at $212.62, up 3.06% over 7 days. The bill has already been signed into law, so no further legislative steps remain for this specific reauthorization. This reauthorization provides long-term visibility for companies operating in the substance use disorder and mental health treatment space. The consistent federal support through FY2030 reduces policy uncertainty and underpins demand for services and products in this sector.